Growth hormone analog may reduce risk of fatty liver disease in HIV-infected patients

Sunday, July 20, 2014 - 23:01 in Health & Medicine

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study. In human immunodeficiency virus (HIV) infection, abdominal fat accumulation is associated with ectopic (out of place) fat accumulation in the liver. Nonalcoholic fatty liver disease (NAFLD) may progress to end-stage liver disease and liver cancer.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net